Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation + sintilimab + fruquintinib
- Development stage
- Preclinical
- Lead developer
- Eighth Affiliated Hospital of Sun Yat-sen University
- Modality
- Small Molecules, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravenous, Rectal
01
Overview
A combination therapy consisting of fecal microbiota transplantation (FMT), sintilimab, and fruquintinib. FMT involves transferring fecal bacteria from a healthy donor to a recipient to restore gut microbiota balance. Fruquintinib is a highly selective oral tyrosine kinase inhibitor targeting VEGFR-1, -2, and -3, inhibiting angiogenesis and tumor growth. Sintilimab is a PD-1 inhibitor. This specific combination may be investigated for potential synergistic effects in treating colorectal cancer or other gastrointestinal malignancies.
- Brand names
- TyvytElunate
- Other names
- FMT + Sintilimab + Fruquintinib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on fecal microbiota transplantation + sintilimab + fruquintinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation + sintilimab + fruquintinib.